Stocks to Watch: Intel, PTC Therapeutics, KLA
By Sabela Ojea
Intel on Thursday delivered a muted outlook for sales in its current quarter. Shares of the chipmaker dropped 10%, to $44.52, in after-hours trading.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on PTC Therapeutics' Translarna authorization following a re-examination procedure. Shares of the biopharmaceutical company declined 12%, to $23.50, in after-hours trading.
KLA posted a profit miss in its fiscal second quarter amid weaker demand for its products. Shares of the maker of equipment for the semiconductor industry fell 5.9%, to $603.75, in after-hours trading.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 25, 2024 18:44 ET (23:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks